生物制药公司Actuate Therapeutics Inc宣布,已正式启动一项战略研究计划。该计划的核心目标是评估其核心候选药物Elraglusib与Ras抑制剂联合使用的潜力。这项研究旨在探索新的治疗途径,为相关疾病领域的患者带来新的希望。
生物制药公司Actuate Therapeutics Inc宣布,已正式启动一项战略研究计划。该计划的核心目标是评估其核心候选药物Elraglusib与Ras抑制剂联合使用的潜力。这项研究旨在探索新的治疗途径,为相关疾病领域的患者带来新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.